A PHASE 1 STUDY TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE AND PHASE 2/3 PIVOTAL CONFIRMATORY CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF OCU410ST FOR STARGARDT DISEASE
Latest Information Update: 14 Aug 2025
At a glance
- Drugs OCU 410 ST (Primary)
- Indications Cone rod dystrophies; Retinitis pigmentosa; Stargardt disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms GARDian3
- Sponsors Ocugen
Most Recent Events
- 29 Jul 2025 Protocol has been amended with change in Phase, endpoints and patient number.
- 29 Jul 2025 Planned number of patients changed from 42 to 51.
- 29 Jul 2025 Planned End Date changed from 28 Oct 2025 to 28 Sep 2026.